Thanks for signing up!

Look for the Digest in your email twice a month.

Follow Us

Sign up for our Digest to receive the latest agronomic insights and crop management advice for your primary growing region delivered twice a month to your inbox.

Warm Weather in the South Sets Stage for Diseases

February 27, 2017

Warm weather helps diseases thrive, and with the mild winter in the south, growers should be prepared for significant disease pressure this season. Being proactive will be key.

How can you protect your crops from diseases? Fungicides can play an important role in protecting your crop by helping to create a protective layer against damaging fungi. Be sure to use an integrated management program that combines:

  • Cultural practices
  • Varieties with genetic resistance
  • Fungicides

Trivapro® fungicide combines 3 modes of action for the hardest-working, longest-lasting, broad-spectrum disease control on the market with preventive and curative disease control that greatly minimizes the potential for resistance development.

During its first season, Trivapro extended residual disease control weeks longer than competitive brands and helped boost yield:

  • An average of 27 bushels per acre (bu/A) more corn than untreated1
  • An average of 8 bu/A more soybeans than untreated2

Trivapro is also the new market leader in 17 different categories*, including:

  • Overall brand preference
  • Higher yields
  • Long-lasting curative and preventive disease control
  • Improved stalk strength and harvestability

AR photo

Trivapro yielded 12.5 bu/a over Headline AMP® fungicide. Additional revenue = $43.75 per acre over Headline AMP. Syngenta trial, 2016.

Protecting crops with a combination of cultural practices and fungicides is key to staying ahead of diseases and growing more.

Sign up for the Know More, Grow More Digest to receive twice monthly agronomic e-mail updates pertinent to your area.

Syngenta hereby disclaims liability for third party websites.

* Trivapro ratings based on first-year users surveyed by Stratus market research.

1 Based on 48 non-replicated trials in the U.S. in 2016.

2 Based on 9 large plot trials in the U.S. in 2016.